Form 4: Agomab Therapeutics CFO Buys Shares
Insider Transaction (Form 4)
Pierre Thadee Victor Kemula, Chief Financial Officer of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 6, 2026.
Summary
- Open-market purchase: acquired 3,000 Common shares at $8.67 ($26,010) on October 6, 2026; holds 3,000 after (Direct).
- Open-market purchase: acquired 5,000 Common shares at $8.57 ($42,850) on October 6, 2026; holds 8,000 after (Direct).
- Open-market purchase: acquired 2,000 Common shares at $8.54 ($17,080) on October 6, 2026; holds 10,000 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $85,940, committing personal capital to the stock.
Insider Transactions
Pierre Thadee Victor Kemula — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Open-market purchase | Common shares | 3,000 | $9 | $26.0K | 3,000 |
| 2026-10-06 | Open-market purchase | Common shares | 5,000 | $9 | $42.9K | 8,000 |
| 2026-10-06 | Open-market purchase | Common shares | 2,000 | $9 | $17.1K | 10,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Open-market purchase (3,000 shares) |
| 2026-10-06 | Open-market purchase (5,000 shares) |
| 2026-10-06 | Open-market purchase (2,000 shares) |
Keywords
insider transaction, Form 4, AGMB, AgomAb Therapeutics NV, bullish, Pierre Thadee Victor Kemula
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.